Harvard Bioscience, Inc.
HBIOHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframePart of the healthcare sector, Harvard Bioscience, Inc. (HBIO) is listed under Medical Instruments & Supplies. The $27.2M market capitalization puts HBIO squarely in micro-cap range for its industry. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
Market Cap
$27.2M
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
13.73
EPS (TTM)
$-2.18
EPS (Fwd)
$0.44
ROE
-78.6%
ROA
1.7%
Cash
$7.1M
Total Debt
$44.1M
Free CF
$7.8M
52W Change
37.3%
Annual Financials
Cash vs Debt
Where HBIO stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, HBIO finished 1.00% below its 150-day moving average ($5.99) and 1.72% above its 200-day moving average ($5.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HBIO overbought or oversold?
At the July 15, 2026 close, HBIO's RSI(14) was 47.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, HBIO has $7.1M in cash with $44.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $7.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -78.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 1.7% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $118.9M (2021) to $86.5M (2025), a 27% decline worth watching.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Harvard Bioscience, Inc.'s trajectory.